



Complete Summary

GUIDELINE TITLE

Hormone replacement therapy.

BIBLIOGRAPHIC SOURCE(S)

Singapore Ministry of Health, Singapore Academy of Medicine, Chapter of Obstetricians and Gynaecologists. Hormone replacement therapy. Singapore: Singapore Ministry of Health; 2004 Apr. 30 p. [51 references]

GUIDELINE STATUS

This is the current release of the guideline.

COMPLETE SUMMARY CONTENT

SCOPE
METHODOLOGY - including Rating Scheme and Cost Analysis
RECOMMENDATIONS
EVIDENCE SUPPORTING THE RECOMMENDATIONS
BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS
CONTRAINDICATIONS
QUALIFYING STATEMENTS
IMPLEMENTATION OF THE GUIDELINE
INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT
CATEGORIES
IDENTIFYING INFORMATION AND AVAILABILITY
DISCLAIMER

SCOPE

DISEASE/CONDITION(S)

- Symptoms of menopause, including vasomotor symptoms, vaginal dryness, and urinary symptoms
- Premature menopause

Note: Conditions for which hormone replacement therapy is NOT indicated are also discussed. These include osteoporosis, heart disease, dementia, and colorectal cancer.

GUIDELINE CATEGORY

Evaluation
Management

Prevention
Treatment

CLINICAL SPECIALTY

Family Practice
Geriatrics
Obstetrics and Gynecology

INTENDED USERS

Advanced Practice Nurses
Allied Health Personnel
Pharmacists
Physicians

GUIDELINE OBJECTIVE(S)

- To address the following issues:
 - Indications for the use of hormone replacement therapy in the healthy postmenopausal woman
 - Safety issues in the use of hormone replacement therapy
 - Principles of treatment, dosing, and optimal duration of therapy
 - Treatment of premature menopause
 - Answers to frequently asked questions about hormone replacement therapy
- To discuss the implications of the Women ' s Health Initiative study (WHI), a large randomized controlled trial, on the role of hormone replacement therapy in stroke, cardiovascular disease, and various cancers

TARGET POPULATION

Women in Singapore with premature menopause or symptoms of menopause

INTERVENTIONS AND PRACTICES CONSIDERED

Hormone replacement therapy, including indications for use, dosage, duration, and route of medications:

1. Estrogens, oral: conjugated equine estrogen (Premarin); estradiol (Estrofem); estradiol valerate (Progynova)
2. Estrogens, transdermal: estradiol patch (Estraderm); estrogel; estradiol hemihydrate (Estreva gel)
3. Progestogens: medroxyprogesterone acetate (Provera); dydrogesterone (Duphaston); norethisterone (Micronor); intrauterine L-norgestrel system (Mirena); micronised progesterone (Utrogestan)
4. Cyclical combined therapies: estradiol valerate and norgestrel (Progyluton); estradiol valerate and cyproterone acetate (Climens); conjugated equine estrogen and norgestrel (Prempak-C); conjugated equine estrogen and medroxyprogesterone acetate (Premelle cycle 5); estradiol and

- dydrogesterone (Femoston); estradiol and norethisterone acetate (Trisequens)
5. Continuous combined therapies: conjugated equine estrogen and medroxyprogesterone acetate (Premelle 5 or Premelle 2.5); estradiol and norethisterone acetate (Kliogest or Activelle).
 6. Local therapy: estradiol pessary (Vagifem); conjugated equine estrogen cream (Premarin cream); colpotrophine 1% cream; colpotrophine pessary 10%; estradiol ring (Estring)

MAJOR OUTCOMES CONSIDERED

- Relief of menopausal symptoms
- Long-term risks of prolonged estrogen deficiency
- Adverse effects of hormone replacement therapy, both short-term and long-term

METHODOLOGY

METHODS USED TO COLLECT/SELECT EVIDENCE

Searches of Electronic Databases

DESCRIPTION OF METHODS USED TO COLLECT/SELECT THE EVIDENCE

Not stated

NUMBER OF SOURCE DOCUMENTS

Not stated

METHODS USED TO ASSESS THE QUALITY AND STRENGTH OF THE EVIDENCE

Weighting According to a Rating Scheme (Scheme Given)

RATING SCHEME FOR THE STRENGTH OF THE EVIDENCE

Levels of Evidence

Level Ia: Evidence obtained from meta-analysis of randomised controlled trials

Level Ib: Evidence obtained from at least one randomised controlled trial

Level IIa: Evidence obtained from at least one well-designed controlled study without randomisation

Level IIb: Evidence obtained from at least one other type of well-designed quasi-experimental study

Level III: Evidence obtained from well-designed nonexperimental descriptive studies, such as comparative studies, correlation studies, and case studies

Level IV: Evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities

METHODS USED TO ANALYZE THE EVIDENCE

Review of Published Meta-Analyses
Systematic Review

DESCRIPTION OF THE METHODS USED TO ANALYZE THE EVIDENCE

Not stated

METHODS USED TO FORMULATE THE RECOMMENDATIONS

Expert Consensus

DESCRIPTION OF METHODS USED TO FORMULATE THE RECOMMENDATIONS

These guidelines were developed by a workgroup made up of specialists in the field of obstetrics and gynaecology with a special interest in hormone replacement therapy and care of menopausal woman, as well as a family practitioner. An exhaustive search into the medical literature as well as guidelines from various colleges around the world formed the basis of these guidelines and recommendations.

RATING SCHEME FOR THE STRENGTH OF THE RECOMMENDATIONS

Grades of Recommendations

Grade A (evidence levels Ia, Ib): Requires at least one randomised controlled trial as part of the body of literature of overall good quality and consistency addressing the specific recommendation.

Grade B (evidence levels IIa, IIb, III): Requires availability of well conducted clinical studies but no randomised clinical trials on the topic of recommendation.

Grade C (evidence level IV): Requires evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. Indicates absence of directly applicable clinical studies of good quality.

GPP (good practice points): Recommended best practice based on the clinical experience of the guideline development group.

COST ANALYSIS

A formal cost analysis was not performed and published cost analyses were not reviewed.

METHOD OF GUIDELINE VALIDATION

Not stated

DESCRIPTION OF METHOD OF GUIDELINE VALIDATION

Not applicable

RECOMMENDATIONS

MAJOR RECOMMENDATIONS

The recommendations that follow are those from the guideline's executive summary; detailed recommendations can be found in the original guideline document. Each recommendation is rated based on the level of the evidence and the grades of recommendation. Definitions of the grades of the recommendations (A, B, C, Good Practice Points [GPP]) and level of the evidence (Level I–Level IV) are presented at the end of the Major Recommendations field.

A – Hormone replacement therapy (HRT) is recommended for the short-term control of vasomotor symptoms, vaginal dryness, and urinary symptoms in menopause. **(Grade A, Level Ib)**

C - Combination HRT should not be used to reduce the risk of osteoporosis and subsequent fractures if it is the only indication for starting hormone replacement therapy. Alternatives such as bisphosphonates (Black et al., 1996) and raloxifene (Ettinger et al., 1999) should instead be considered. **(Grade C, Level IV)**

A - HRT should not be used for primary or secondary prevention of heart disease. **(Grade A, Level Ib)**

C - Prevention of colorectal cancer should not be the reason for long-term hormone replacement therapy. **(Grade C, Level IV)**

A - HRT is not recommended for the prevention of Alzheimer's disease or dementia. **(Grade A, Level Ib)**

A - The use of unopposed HRT in a woman with an intact uterus has been shown to increase the risk of endometrial cancer by several fold (Chlebowski et al., 2003; Shields et al., 1999). Therefore combined hormone replacement therapy should be used in patients with intact uteri. **(Grade A, Level Ia)**

C - HRT is the cornerstone in the management of patients with premature menopause. It is effective in the relief of menopausal symptoms and protects against the long-term risks associated with prolonged estrogen deficiency ("Risks and benefits of estrogen," 2002; Davis, 1996; Willhite & O'Connell, 2001; Cardozo et al, 1998). **(Grade C, Level IV)**

Grades of Recommendations

Grade A (evidence levels Ia, Ib): Requires at least one randomised controlled trial as part of the body of literature of overall good quality and consistency addressing the specific recommendation.

Grade B (evidence levels IIa, IIb, III): Requires availability of well conducted clinical studies but no randomised clinical trials on the topic of recommendation.

Grade C (evidence level IV): Requires evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities. Indicates absence of directly applicable clinical studies of good quality.

GPP (good practice points): Recommended best practice based on the clinical experience of the guideline development group.

Levels of Evidence

Level Ia: Evidence obtained from meta-analysis of randomised controlled trials

Level Ib: Evidence obtained from at least one randomised controlled trial

Level IIa: Evidence obtained from at least one well-designed controlled study without randomisation

Level IIb: Evidence obtained from at least one other type of well-designed quasi-experimental study

Level III: Evidence obtained from well-designed nonexperimental descriptive studies, such as comparative studies, correlation studies and case studies

Level IV: Evidence obtained from expert committee reports or opinions and/or clinical experiences of respected authorities

CLINICAL ALGORITHM(S)

None provided

EVIDENCE SUPPORTING THE RECOMMENDATIONS

REFERENCES SUPPORTING THE RECOMMENDATIONS

[References open in a new window](#)

TYPE OF EVIDENCE SUPPORTING THE RECOMMENDATIONS

The type of supporting evidence is identified and graded for each recommendation (see "Major Recommendations")

BENEFITS/HARMS OF IMPLEMENTING THE GUIDELINE RECOMMENDATIONS

POTENTIAL BENEFITS

- Short-term hormone replacement therapy (HRT) helps control menopausal vasomotor symptoms, urinary symptoms, and symptoms of vaginal dryness.
- HRT is the cornerstone in the management of patients with premature menopause. It is effective in the relief of significant menopausal symptoms and protects against the long-term risks associated with prolonged estrogen deficiency.
- In the Women's Health Initiative (WHI) study, a large randomized controlled trial, combination HRT was associated with reduced risk of endometrial cancer, hip fractures, and colorectal cancers. Estrogen alone appears to marginally decrease risk of hip fracture in postmenopausal women with hysterectomies.

POTENTIAL HARMS

- Combination hormone replacement therapy (HRT) is associated with significant risk of deep vein thrombosis and pulmonary embolism.
- Combination HRT is associated with a small increase of ischaemic stroke in healthy postmenopausal women. Results with estrogen alone replacement indicated that the increased risk of stroke is similar to that found in the trial of estrogen plus progestin when it was stopped after 5.2 years of follow up.
- Combination HRT, and unopposed estrogen replacement therapy are associated with a small but significant risk of breast cancer. Estrogen only therapy did not show an increased risk in hysterectomized women.
- Combination HRT is associated with a doubled rate of dementia including Alzheimer's disease.
- There is evidence that mammographic changes associated with hormone usage may hinder and delay the diagnosis of breast cancer.
- Other HRT side effects are breast tenderness, irregular vaginal bleeding, and headaches.

CONTRAINDICATIONS

CONTRAINDICATIONS

The use of unopposed hormone replacement therapy (HRT) in a woman with an intact uterus has been shown to increase the risk of endometrial cancer by several fold. Therefore combined HRT should be used in patients with intact uteri.

QUALIFYING STATEMENTS

QUALIFYING STATEMENTS

- These guidelines are not intended to serve as a standard of medical care. Standards of medical care are determined on the basis of all clinical data available for an individual case and are subject to change as scientific knowledge advances and patterns of care evolve.

- The contents of this publication are guidelines to clinical practice, based on the best available evidence at the time of development. Adherence to these guidelines may not ensure a successful outcome in every case, nor should they be construed as including all proper methods of care or excluding other acceptable methods of care. Each physician is ultimately responsible for the management of his/her unique patient in the light of the clinical data presented by the patient and the diagnostic and treatment options available.

IMPLEMENTATION OF THE GUIDELINE

DESCRIPTION OF IMPLEMENTATION STRATEGY

The guidelines propose the following audit parameter:

Percentage of women with intact uteri on hormone replacement therapy receiving estrogen-only therapy. (The use of unopposed hormone replacement therapy in a woman with an intact uterus has been shown to increase the risk of endometrial cancer by several fold. Therefore combined hormone replacement therapy should be used in patients with intact uteri.)

INSTITUTE OF MEDICINE (IOM) NATIONAL HEALTHCARE QUALITY REPORT CATEGORIES

IOM CARE NEED

Getting Better
Staying Healthy

IOM DOMAIN

Effectiveness

IDENTIFYING INFORMATION AND AVAILABILITY

BIBLIOGRAPHIC SOURCE(S)

Singapore Ministry of Health, Singapore Academy of Medicine, Chapter of Obstetricians and Gynaecologists. Hormone replacement therapy. Singapore: Singapore Ministry of Health; 2004 Apr. 30 p. [51 references]

ADAPTATION

Not applicable: The guideline was not adapted from another source.

DATE RELEASED

2004 Apr

GUIDELINE DEVELOPER(S)

Chapter of Obstetricians and Gynaecologists, Academy of Medicine (Singapore) -
Medical Specialty Society
Singapore Ministry of Health - National Government Agency [Non-U.S.]

SOURCE(S) OF FUNDING

Singapore Ministry of Health (MOH)

GUIDELINE COMMITTEE

Workgroup on Hormone Replacement Therapy

COMPOSITION OF GROUP THAT AUTHORED THE GUIDELINE

Workgroup Members: Dr Yu Su Ling, Head & Senior Consultant, Dept of Obstetrics and Gynaecology, Singapore General Hospital (Chairman); Dr Lee Puay Hoon, Julinda, Associate Consultant, Dept of Obstetrics and Gynaecology, Singapore General Hospital; Dr Lisa Chin Yue Kim, Chin Y K Clinic for Women and Menopause Centre, Gleneagles Medical Centre; Dr Phyllis Liauw, TLC Gynaecology Practice, Thomson Medical Centre; Dr Sandy Lek, Joo Chiat Clinic for Women; Dr Ling Yee Kiang, Geylang Polyclinic; Dr Yeoh Swee Choo, The Obstetrics & Gynaecology Practice, Mount Elizabeth Medical Centre; Dr Khong Chit Chong, Head and Senior Consultant, Menopause Unit, KK Women & Children's Hospital; Dr Oei Pau Ling, My Gynae Women's Clinic, Gleneagles Medical Centre; Dr Loh Foo Hoe, Women's Specialist Associates, Mount Elizabeth Medical Centre

FINANCIAL DISCLOSURES/CONFLICTS OF INTEREST

Not stated

GUIDELINE STATUS

This is the current release of the guideline.

GUIDELINE AVAILABILITY

Electronic copies: Available in Portable Document Format (PDF) from the [Singapore Ministry of Health Web site](#).

Print copies: Available from the Singapore Ministry of Health, College of Medicine Building, Mezzanine Floor 16 College Rd, Singapore 169854.

AVAILABILITY OF COMPANION DOCUMENTS

None available

PATIENT RESOURCES

None available

NGC STATUS

This NGC summary was completed by ECRI on July 28, 2004.

COPYRIGHT STATEMENT

This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please contact the Ministry of Health, Singapore by e-mail at MOH_INFO@MOH.GOV.SG.

DISCLAIMER

NGC DISCLAIMER

The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.

All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.

Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at <http://www.guideline.gov/about/inclusion.aspx>.

NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.

Readers with questions regarding guideline content are directed to contact the guideline developer.

© 1998-2008 National Guideline Clearinghouse

Date Modified: 9/29/2008

